Ainos, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ainos, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.2K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $20.7K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $122.1K | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $3.52M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $594.6K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $16.6K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.7K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $77.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $250.9K | Apr 16, 2019 |
| FY2015 | Dec 31, 2015 | $0 | Mar 30, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($31.9K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($253.7K) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.41M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $410.4K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $5.3K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $12.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $190.6K | Apr 16, 2019 |
| FY2013 | Dec 31, 2012 | $318 | Apr 15, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.77M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($14.86M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($13.77M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($14.01M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($3.89M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($1.45M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.58M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.34M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($617.4K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($670.0K) | Apr 18, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.99M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($13.84M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($13.21M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($13.98M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($3.87M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($1.44M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.58M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.33M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($579.8K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($667.1K) | Apr 18, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.75M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.41M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.32M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $6.85M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.92M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $389 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $52.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $32.6K | Mar 30, 2020 |
| FY2013 | Dec 31, 2013 | $133.0K | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | $199.6K | Apr 15, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.34M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.40M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.64M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $8.54M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.36M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $1.45M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.53M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.31M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $770.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $667.1K | Apr 18, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.61M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.81M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.69M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($3.04M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($1.25M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($499.6K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($909.5K) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.01M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($484.6K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($520.8K) | Apr 18, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.6K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $21.3K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $93.0K | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $633.8K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $143.8K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.9K | Mar 30, 2020 |
| FY2017 | Dec 31, 2016 | $47.7K | Apr 18, 2018 |
| FY2016 | Dec 31, 2015 | $7.1K | Apr 17, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.87M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $28.82M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $31.84M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $37.11M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $40.82M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $260.3K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $596.6K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.46M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.29M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $462.7K | Apr 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.31M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.30M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.39M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $2.48M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $30.63M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $1.10M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $753.3K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $733.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.82M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.27M | Apr 18, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.56M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $15.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $24.45M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $34.63M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $10.20M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | ($838.3K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2019 | ($156.7K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $730.1K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $470.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($809.9K) | Apr 16, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($67.52M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($52.75M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($37.89M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($24.12M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($10.11M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($6.22M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($4.77M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($3.19M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($1.88M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.27M) | Apr 18, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $417.4K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.89M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.89M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.85M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.75M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $22.2K | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $409.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.28M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $2.04M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $134.1K | Apr 16, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 7, 2025 |
| FY2011 | Dec 31, 2011 | 0 | Apr 19, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Apr 19, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 7, 2025 |
| FY2013 | Dec 31, 2013 | 0 | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | 0 | Apr 15, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Apr 1, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Apr 19, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.88M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 3.09M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 4.68M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 4.00M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 9.63M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | 42.07M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 40.52M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 39.12M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 23.16M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 21.92M | Apr 18, 2018 |